Incyte Corporation (INCY)

NASDAQ
Currency in USD
68.46
+0.19(+0.28%)
Closed·
After Hours
68.25-0.22(-0.32%)
·
INCY Scorecard
Full Analysis
Management has been aggressively buying back shares
INCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
67.8669.19
52 wk Range
53.5683.95
Key Statistics
Edit
Prev. Close
68.27
Open
68.47
Day's Range
67.86-69.19
52 wk Range
53.56-83.95
Volume
2.34M
Average Volume (3m)
2.05M
1-Year Change
8.29%
Book Value / Share
18.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INCY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
75.15
Upside
+9.77%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Incyte Corporation News & Analysis

Show more

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Employees
2617

Incyte Corporation SWOT Analysis


Pipeline Potential
Explore Incyte's diverse product pipeline, focusing on dermatology treatments like povorcitinib for hidradenitis suppurativa and Opzelura for atopic dermatitis
Jakafi's Sunset
Delve into Incyte's strategy to offset the looming $3 billion revenue gap from Jakafi's patent expiration in 2029 through pipeline development and potential acquisitions
Market Dynamics
Analyst price targets range from $52 to $74, reflecting mixed views on Incyte's ability to navigate competitive pressures and capitalize on growth opportunities
Financial Health
Learn about Incyte's strong cash position of $2.2 billion, robust revenue growth, and aggressive share buyback program, signaling management's confidence in future prospects
Read full SWOT analysis

Incyte Corporation Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $1.16 beat forecast by 11.5%; revenue up 20% YoY to $1.05B, exceeding expectations
  • Stock rose 3.66% premarket to $61.70; company maintains robust financial health with strong cash flow metrics
  • Successful launch of Nictimvo in third-line chronic GVHD; raised full-year revenue guidance for Jakafi to $2.95-$3B
  • Plans to launch four new products in 2025 and initiate at least three Phase III studies
  • Net income expected to grow; analysts maintain positive consensus recommendation of 2.37
Last Updated: 29-04-2025, 06:58 pm
Read Full Transcript

Compare INCY to Peers and Sector

Metrics to compare
INCY
Peers
Sector
Relationship
P/E Ratio
623.0x−2.7x−0.5x
PEG Ratio
−6.42−0.020.00
Price/Book
3.6x0.0x2.6x
Price / LTM Sales
3.0x94.4x3.0x
Upside (Analyst Target)
5.7%322.8%52.4%
Fair Value Upside
Unlock9.5%8.7%Unlock

Analyst Ratings

11 Buy
15 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 75.15
(+9.77% Upside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
1.16 / 1.04
Revenue / Forecast
1.05B / 990.99M
EPS Revisions
Last 90 days

INCY Income Statement

FAQ

What Is the Incyte (INCY) Stock Price Today?

The Incyte stock price today is 68.46.

What Stock Exchange Does Incyte Trade On?

Incyte is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Incyte?

The stock symbol for Incyte is "INCY."

What Is the Incyte Market Cap?

As of today, Incyte market cap is 13.25B.

What Is Incyte's Earnings Per Share (TTM)?

The Incyte EPS (TTM) is 0.11.

When Is the Next Incyte Earnings Date?

Incyte will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is INCY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Incyte Stock Split?

Incyte has split 2 times.

How Many Employees Does Incyte Have?

Incyte has 2617 employees.

What is the current trading status of Incyte (INCY)?

As of 22 Jun 2025, Incyte (INCY) is trading at a price of 68.46, with a previous close of 68.27. The stock has fluctuated within a day range of 67.86 to 69.19, while its 52-week range spans from 53.56 to 83.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.